Serum Procalcitonin (PCT) Level In Acute Kidney Injury (AKI) In Critical Patients: Acute Kidney Injury (AKI) In Critical Patients

Azwar Iwan Tona; Maimun Syukri

doi:10.47353/jsocmed.v1i2.8

Serum Procalcitonin (PCT) Level In Acute Kidney Injury (AKI) In Critical Patients

Acute Kidney Injury (AKI) In Critical Patients

Azwar Iwan Tona
Department of Emergency, Datu Beru, Aceh Tengah, Indonesia
Maimun Syukri
Department of Internal Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia

Abstract

Early prediction and avoidance of aggravation of AKI will be useful in identifying patients at risk of developing a higher degree of AKI. Many studies have been conducted to prevent AKI and find biomarkers to predict AKI. Many studies have identified biomarkers of AKI, such as neutrophil-associated lipocalin (NGAL), cystatin C, interleukin-18, and tissue inhibitors of metalloproteinase-2 (TIMP-2). Yet few have investigated the role of PCT as a predictor of AKI. The pathophysiological mechanisms that explain the association between serum PCT and AKI remain unclear. Various inflammatory responses are thought to play a role in the AKI development. PCT acts as a chemoattractant in the inflammation area and causes more monocytes to invade the inflammation. PCT is initially produced in adherent monocytes and then contributes to an increase in circulating PCT by attracting parenchymal cells as they attach directly to activated monocytes. High PCT levels ultimately act as a direct chemoattractant to monocyte counts.

Similar Articles

M Yusuf Adira Putra, Amira Permatasari Tarigan, Andika Pradana, Riska Resti, Adini Arifah Ramadhani, Syafiah Amalina Nasution, A Study of Relationship Between Asthma Control Test, Lung Function, & Hospitalization , Journal of Society Medicine: Vol. 3 No. 12 (2024): December

<< < 1 2 3

You may also start an advanced similarity search for this article.

PDF

Published at

16. November 2022
https://doi.org/10.47353/jsocmed.v1i2.8
Issue:

Vol. 1 No. 2 (2022): November
Section:

Articles
Keywords:

PCT AKI Early prediction
References:

Pruchnicki MC, Dasta JF, Martinez MD, et al. Acute renal failure in hospitalized patients: Part II. Ann Pharmacother 2002; 36: 1430–1442.

Pruchnicki MC, Dasta JF, Martínez MD, et al. Acute renal failure in hospitalized patients: Part I. Ann Pharmacother 2002; 36: 1261–1267.

Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41: 1411–1423.

Dennen P, Douglas IS, Anderson R. Acute kidney injury in the intensive care unit: An update and primer for the intensivist. Critical Care Medicine 2010; 38: 261–275.

Vaidya VS, Ferguson MA, Bonventre J V. Biomarkers of Acute Kidney Injury. Annu Rev Pharmacol Toxicol 2008; 48: 463–493.

Edelstein CL, Akcay A, Nguyen Q. Mediators of inflammation in acute kidney injury. Mediators of Inflammation; 2009. Epub ahead of print 2009. DOI: 10.1155/2009/137072.

Su Y, Gong Z, Wu Y, et al. Diagnostic value of urine tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 for acute kidney injury: A meta-analysis. PLoS One; 12. Epub ahead of print 1 January 2017. DOI: 10.1371/journal.pone.0170214.

Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med 2018; 379: 236–249.

Chun K, Chung W, Kim AJ, et al. Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients. Sci Rep 2019; 9: 1–8.

Heredia-Rodríguez M, Bustamante-Munguira J, Fierro I, et al. Procalcitonin cannot be used as a biomarker of infection in heart surgery patients with acute kidney injury. J Crit Care 2016; 33: 233–239.

Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43: 304–377.

Itenov TS, Jensen J-U, Ostrowski SR, et al. Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. Shock 2017; 47: 696–701.

Araujo M, Doi SQ, Palant CE, et al. Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: Implications for septic renal injury. Inflamm Res 2013; 62: 887–894.

Zheng W, Liang X, Shui L, et al. Serum Procalcitonin Correlates with Renal Function in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Cell Physiol Biochem 2018; 50: 1794–1803.

Steinbach G, Bölke E, Grünert A, et al. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr 2004; 116: 849–853.

Nakamura Y, Murai A, Mizunuma M, et al. Potential use of procalcitonin as biomarker for bacterial sepsis inpatients with or without acute kidney injury. J Infect Chemother 2015; 21: 257–263.

Oczenski W, Fitzgerald RD, Schwarz S. Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol 1998; 15: 202–9.

Meisner M, Brunkhorst FM, Reith HB, et al. Clinical experiences with a new semi-quantitative solid phase immunoassay for rapid measurement of procalcitonin. Clin Chem Lab Med 2000; 38: 989–95.

Meisner M. Biomarkers of sepsis: clinically useful? Curr Opin Crit Care 2005; 11: 473–80.

Kristopher A. M. and Nikola A. B. Procalcitonin. Clin Lab News 2009; 35: 1–5.

Rau B, Krüger C, Schilling M. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbeck’s Arch Surg 2004; 134–144.

O’Connor E, Venkatesh B, Lipman J, et al. Procalcitonin in critical illness. Crit Care Resusc 2001; 3: 236–43.

Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 2000; 26: 1193–1200.

Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 323: 17–29.

Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159: 253–64.

Sparrow HG, Swan JT, Moore LW, et al. Disparate outcomes observed within Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury stage 1. Epub ahead of print 2019. DOI: 10.1016/j.kint.2018.11.030.

Kidney Disease Improving Global Outcome. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2: 124–138.

United State Renal Data System. Chapter 5: Acute Kidney Injury. In: 2018 USRDS Annual Data Report. 2018, pp. 100–124.

Goyal A, Daneshpajouhnejad P, Hashmi MF, et al. Acute Kidney Injury. StatPearls Publishing, http://www.ncbi.nlm.nih.gov/pubmed/28722925 (2020, accessed 31 October 2020).

Markum H. Gangguan Ginjal Akut. In: Buku Ajar Ilmu Penyakit Dalam. Jakarta: Interna Publishing, 2009, p. 1041.

Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. Clin Biochem Rev 2016; 37: 85–98.

Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol 2012; 2: 1303–1353.

Di Lullo L, Ronco C, Cozzolino M, et al. Type-5 Cardiorenal Syndrome (CRS-5): An up to Date. Nephrol @ Point Care 2017; 3: napoc.5000212.

Anathhanam S, Lewington AJP. Acute kidney injury. J R Coll Physicians Edinb 2013; 43: 323–329.

Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE*. Crit Care Med 2007; 35: 1837–1843.

Okusa MD. The Inflammatory Cascade in Acute Ischemic Renal Failure. Nephron 2002; 90: 133–138.

Lemay S, Rabb H, Postler G, et al. Prominent and sustained up-regulation of gp130-signaling cytokines and of the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation 2000; 69: 959–963.

Wiedermann FJ, Kaneider N, Egger P, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med 2002; 30: 1112–1117.

Linscheid P, Seboek D, Schaer DJ, et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004; 32: 1715–1721.

Chancharoenthana W, Leelahavanichkul A, Eiam-Ong S. Sepsis-associated Acute Kidney Injury. In: Sepsis. InTech. Epub ahead of print 23 August 2017. DOI: 10.5772/intechopen.69612.

Bilgili B, Haliloğlu M, Cinel İs. Sepsis ve akut böbrek hasarı. Turk Anesteziyoloji ve Reanimasyon Dernegi Dergisi 2014; 42: 294–301.

Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: Pathophysiology, prevention and future therapies. Current Opinion in Critical Care 2014; 20: 588–595.

Jefferson J, Joshua M, Schrier R. Pathophysiology and Etiology of Acute Kidney Injury. In: Abdominal Key. 2016.

Honore PM, Jacobs R, Hendrickx I, et al. Prevention and treatment of sepsis-induced acute kidney injury: an update. Annals of Intensive Care 2015; 5: 1–10.

Melyda. Diagnosis dan Tatalaksana Acute Kidney Injury (AKI) pada Syok Septik. CKD 2017; 41: 15.

Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014; 41: 3–11.

Emlet DR, Shaw AD, Kellum JA. Sepsis-Associated AKI: Epithelial Cell Dysfunction. Seminars in Nephrology 2015; 35: 85–95.
Share:

Z

Iwan Tona, A., & Syukri, M. (2022). Serum Procalcitonin (PCT) Level In Acute Kidney Injury (AKI) In Critical Patients: Acute Kidney Injury (AKI) In Critical Patients. Journal of Society Medicine, 1(2), 44–55. https://doi.org/10.47353/jsocmed.v1i2.8